We are advancing a pipeline of multiple cellular and acellular product candidate utilizing Lung Spheroid Cells (LSCs). Our pipeline includes BRS001, our lead investigational new drug, in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF).